4results about How to "Reduce body fat" patented technology

The invention discloses an intelligent nutrition evaluation and nutrition movement intervention system based on a nutrition and movement principle. The method comprises the following steps: establishing food dietary nutrition content data, food component content data and movement intervention data required by overweight and obesity, hyperlipidemia, sarcopenia and osteoporosis groups, and algorithm evaluation data; collecting basic information data and dietary intake food information data of the group; designing a dietary nutrition algorithm and an exercise intervention demand amount algorithm required by the group to obtain daily dietary nutrition, food type and quantity intake level and exercise intervention demand amount; designing evaluation standards and methods of dietary nutrition and exercise intervention demand quantity required by the group; comprehensive analysis and evaluation are carried out on the calculation result of the dietary nutrition and food types and numbers, the calculation result of the exercise intervention energy demand amount and evaluation standards and methods, and nutrition intervention and exercise intervention guidance suggestions are generated. The method is accurate and scientific in evaluation, is assisted by personalized exercise and fitness guidance, and effectively promotes disease improvement of the group.

The application belongs to the field of drug research and development, and particularly relates to application of an acid glycoprotein ORM in preparation of a drug for treating muscle reduction, and the application uses ORM1 knockout mice to evaluate the role of ORM in muscle reduction, and results show that glucocorticoid (dexamethasone) can induce muscle reduction, which is manifested in that the body weight of mice is reduced, the grip strength is reduced, and the skeletal muscle mass is reduced, and these indexes are more seriously reduced after ORM is knocked out, and exogenous ORM can significantly improve the cell muscle reduction model induced by dexamethasone, thereby providing a new idea for treatment of muscle reduction.

The present invention belongs to the field of drug application, and specifically discloses the use of sarcosine as the only active ingredient in the preparation of drugs for preventing and treating obesity and / or hyperlipidemia. The present invention uses sarcosine to treat elderly mice, and confirms that sarcosine can reduce the total body mass and fat mass, and reduce the body fat rate without affecting the absolute lean body mass. Through tissue staining and biochemical analysis, it is determined that sarcosine can reduce the cross-sectional area of ​​visceral adipose tissue (VAT) cells, upregulate the expression of UCP1, a marker of brown adipose tissue in visceral adipose tissue, and significantly reduce the level of triglycerides in plasma. Sarcosine has practical application value in the treatment of obesity and hyperlipidemia.

The invention features polypeptides that include an extracellular ActRlla variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRlla variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.